In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.
The firm continues to forecast approximately $1.4 billion in revenue from breast cancer indications for Gilead by the year 2025. TD Cowen's analyst remains optimistic about Trodelvy's potential ...
Some results have been hidden because they may be inaccessible to you